8-K: Zomedica Appoints Scott Jordan as New Chief Financial Officer

Zomedica Corp. has appointed Scott Jordan as its new Chief Financial Officer, effective January 1, 2025, bringing over 30 years of experience in the life sciences and diagnostics industries.

Summary

• Zomedica Corp. has announced the appointment of Scott Jordan as its new Chief Financial Officer, effective January 1, 2025.
• Mr. Jordan has over 30 years of experience in the life sciences and diagnostics industries, including C-level roles, business development, and commercialization.
• He founded S. Jordan Associates, a boutique investment bank, in 2020 and has served as its CEO since inception.
• Mr. Jordan has a history of raising capital through private placements, public offerings, and non-dilutive financing, as well as securing licensing agreements and facilitating M&A transactions.
• His previous roles include CFO positions at Inomagen Therapeutics, Iterion Therapeutics, and Salarius Pharmaceuticals.
• At Salarius, he helped the company achieve pivotal financing and scientific milestones, leading to a NASDAQ listing via a reverse merger.
• Mr. Jordan's employment agreement includes a base salary of $350,000 per annum, a potential annual bonus of up to 40%, a $35,000 relocation bonus, and options to purchase 5,000,000 common shares.
• The options will vest over four years, starting one year after the grant date, and expire ten years after the grant date.
• He will also receive standard employee benefits and severance packages in case of termination without cause or following a change of control.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of a highly experienced CFO and the company's recent growth and strong financial position. The forward-looking statements are cautiously optimistic, and the risks are standard for a company in this sector.

Positives

• The appointment of Scott Jordan brings a seasoned executive with extensive experience in finance, business development, and commercialization to Zomedica.
• Mr. Jordan's track record includes successful capital raising, strategic partnerships, and public listings, which could benefit Zomedica's growth.
• The employment agreement includes performance-based incentives, aligning Mr. Jordan's interests with the company's success.
• Zomedica has a strong balance sheet with $78 million in liquidity as of September 30, 2024.

Risks

• The company's future performance is subject to various risks and uncertainties, including the outcome of clinical studies, regulatory approvals, and market competition.
• There is no guarantee that the company's strategies and business plans will yield the expected benefits.
• The company's ability to integrate acquisitions and supply products in response to customer demand is uncertain.
• The company's forward-looking statements are based on management's opinions and estimates, which may not prove to be correct.

Future Outlook

Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally to enhance the quality of care for pets and improve the profitability of veterinary practices.

Management Comments

• Larry Heaton, Zomedica's Chief Executive Officer, stated that Scott Jordan's skills and experience will be increasingly important as the company moves forward.
• Scott Jordan commented that he is honored to join Zomedica and looks forward to leveraging his experience to support the company's growth and deliver value to stakeholders.

Industry Context

The appointment of a seasoned financial executive like Scott Jordan aligns with Zomedica's growth strategy in the competitive veterinary health market, where financial expertise is crucial for expansion and strategic acquisitions.

Comparison to Industry Standards

• Zomedica's 33% revenue growth in 2023 is a strong performance compared to the broader veterinary health industry, which is experiencing steady growth.
• The appointment of a CFO with a background in investment banking and capital raising is a common practice for companies in the life sciences and diagnostics sectors, especially those looking to expand through acquisitions and strategic partnerships.
• Companies like IDEXX Laboratories and Zoetis are established players in the animal health market, and Zomedica's strategic moves, including this CFO appointment, indicate its ambition to compete effectively.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially increasing investor confidence.
• Employees may benefit from Mr. Jordan's leadership and expertise.
• Customers and suppliers may not be directly impacted by this change, but the company's overall financial health and growth could indirectly benefit them.

Next Steps

• Scott Jordan will assume his role as CFO on January 1, 2025.
• The company will likely focus on integrating Mr. Jordan into the team and leveraging his expertise to support its growth initiatives.

Key Dates

Keywords

Chief Financial Officer, CFO, Scott Jordan, Zomedica, Life Sciences, Diagnostics, Finance, Capital Raising, M&A, Employment Agreement, Veterinary Health